TheraRadar
Data updated: May 26, 2026

KIMIDESS (desogestrel)

Women's Health Approved 2015-04-30
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
11
Years on Market

Details

Status
Discontinued
First Approved
2015-04-30
Routes
ORAL-28
Dosage Forms
TABLET

Companies

PH HEALTH
Active Ingredient: DESOGESTREL , ETHINYL ESTRADIOL

KIMIDESS Approval History

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
3 FDA actions from 2015 to 2022
Apr 2022 SUPPL
Label · Labeling
Aug 2017 SUPPL
Label · Labeling
Apr 2015 ORIGINAL
Update

What KIMIDESS Treats

1 FDA approvals

Originally approved for its first indication in 2015 .

  • Other (1)
📋

Clinical Trial Registry

3 trials
Trial Sponsor ID Phase Status Title
NCT01500473 results posted CCI-11-00057 Ph 2 terminated Therapeutic Effect of Desogestrel on Ventilatory Control in Patients With Congenital Central Hypoventilation Syndrome
NCT01738724 FMRPUSP-UROGIN-002 Ph 4 terminated Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin
NCT01243697 RESPIRONDINE P101001 Ph 2, Ph 3 completed Assessment of Desogestrel in Ondine Syndrome
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

KIMIDESS FDA Label Details

Track KIMIDESS with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

FDA Approval: ANDA076681 → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.